VEEV Add to watchlist $167.30 +8.20 (+5.16%) Last updated: Apr 16, 2026 00:44
52-Week Range
$167.30
$148.05 $167.30 $310.50

Fundamentals Overview

Veeva Systems Inc. is near the low of its 52-week range with premium valuation, showing strong upward momentum today.

Valuation premium

P/E 31 PEG 1.14 P/B 3.81 P/S 8.61

Intrinsic value (DCF)

-36.1% downside vs price

Profitability

Net margin 28.4%

Risk (Beta)

1.1 — in line vol

Earnings & growth

EPS $5.40 Rev +3% Profit +3.4% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 65% confidence Risk: Moderate Volatility — Beta 1.1. Diversify and only invest what you can afford to lose.

Supporting (Buy):

Analyst grade: B+

Pressures (Sell):

DCF 36.1% downside vs price · Sentiment weakening (2 downgrades) · 3M vs S&P 500: -28.9% · 3M vs Healthcare sector: -22.2%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$27.50B
P/E (TTM)
30.97
EPS (TTM)
$5.40
Dividend Yield
N/A
52-Week Range
$148.05 - $310.50
Volume vs Avg
N/A
Beta
1.1

About

Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud, a suite of software, data, and analytics solutions, which include Veeva customer relationship management (CRM) and Veeva Medical CRM, Veeva CLM, Veeva CRM MyInsights, Veeva CLM, Veeva CRM Approved Email, Veeva CRM Engage, Veeva Align, Veeva CRM Events Management, Veeva Nitro, Veeva OpenDa...
Sector: Healthcare
Headquarters: US
Employees: 7,291
IPO Date: Oct 2013
Website: www.veeva.com
Beta: 1.1 (More volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 11, Equal Weight: 2, Hold: 2, In Line: 1, Neutral: 4, Outperform: 3, Overweight: 6, Sector Weight: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $106.98; current price is $167.30. That’s a -36.1% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 30.97
DCF value (model) $106.98 (-36.1% vs price)
PEG (TTM) 1.14
P/B (TTM) 3.81
P/S (TTM) 8.61
P/FCF (TTM) 19.79
Liquidity & enterprise
Current Ratio (TTM) 4.89
Quick Ratio (TTM) 4.89
Cash Ratio (TTM) 0.87
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 28.44%
Gross margin (TTM) 75.53%
Operating margin (TTM) 28.68%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for VEEV.

Analyst Sentiment at a Glance

B+ Sentiment Weakening
Buy 11Equal Weight 2Hold 2In Line 1Neutral 4Outperform 3Overweight 6Sector Weight 1
1 upgrade, 2 downgrades
Price Target Consensus
Current $167.30
Median $281.50
Consensus $280.10
Low consensus $205.00
High consensus $333.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Citigroup downgrade Buy Neutral 2026-04-10
Citigroup maintain Buy Buy 2026-03-09
Canaccord Genuity maintain Hold Hold 2026-03-05
UBS maintain Neutral Neutral 2026-03-05
Piper Sandler maintain Overweight Overweight 2026-03-05
Stifel maintain Buy Buy 2026-03-05
Wells Fargo maintain Overweight Overweight 2026-03-05
TD Cowen maintain Buy Buy 2026-03-05
Morgan Stanley maintain Equal Weight Equal Weight 2026-03-05
Needham maintain Buy Buy 2026-03-05
Evercore ISI Group maintain In Line In Line 2026-03-05
Truist Securities maintain Buy Buy 2026-03-05
RBC Capital maintain Outperform Outperform 2026-03-05
Stifel maintain Buy Buy 2026-02-26
Barclays maintain Overweight Overweight 2026-02-25
Oppenheimer maintain Outperform Outperform 2026-02-24
UBS maintain Neutral Neutral 2026-02-20
JP Morgan maintain Overweight Overweight 2026-02-20
Morgan Stanley upgrade Underweight Equal Weight 2026-02-17
Keybanc downgrade Overweight Sector Weight 2025-12-12
Wells Fargo maintain Overweight Overweight 2025-11-25
Citigroup maintain Buy Buy 2025-11-24
Needham maintain Buy Buy 2025-11-21
Canaccord Genuity maintain Hold Hold 2025-11-21
BTIG maintain Buy Buy 2025-11-21
Baird maintain Outperform Outperform 2025-11-21
Barclays maintain Overweight Overweight 2025-11-21
UBS maintain Neutral Neutral 2025-11-21
Needham maintain Buy Buy 2025-10-17
BTIG maintain Buy Buy 2025-10-17